Mots-C
Mitochondrial open reading frame of the 12S rRNA-c, MT-RNR1, Mitochondrial-derived peptide MOTS-c
MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.
Zheng. Yuejun Y; Wei. Zilin Z; Wang. Tianhui T
Key Findings
- MOTS‑c is a 16‑amino‑acid peptide encoded by mitochondrial DNA and can relocate to the nucleus during metabolic stress.
- Circulating MOTS‑c levels decline with age.
- Supplementing MOTS‑c improves glucose metabolism in skeletal muscle and shows promise for diabetes, obesity, cardiovascular disease, insulin resistance, and inflammation.
Practical Outcomes
- For now, the main takeaway is that boosting MOTS‑c might support metabolic health and longevity, but there’s no established dosage or delivery method yet. Keep an eye on emerging studies or synthetic‑biology approaches that could turn MOTS‑c into a practical supplement in the future.
Summary
MOTS‑c is a tiny protein made by mitochondria that can move into the cell nucleus when you’re stressed and help turn on genes that keep cells balanced. Its levels go down as we get older, but giving it to cells improves how muscles handle sugar, hinting it could help with diabetes, weight gain, aging, heart health, and inflammation. The paper mainly reviews what’s known and suggests future ways to use it, but doesn’t give a ready‑to‑use supplement plan.
Abstract
Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c) is a mitochondrial-derived peptide composed of 16 amino acids encoded by the 12S rRNA region of the mitochondrial genome. The MOTS-c protein is transferred to the nucleus during metabolic stress and directs the expression of nuclear genes to promote cell balance. Different tissues co-expressed the protein with mitochondria, and plasma also contained the protein, but its level decreased with age. In addition, MOTS-c has been shown to improve glucose metabolism in skeletal muscle, which indicates its benefits for diseases such as diabetes, obesity, and aging. Nevertheless, MOTS-c has been used less frequently in disease treatment, and no effective method of applying MOTS-c in the clinic has been developed. Throughout this paper, we discussed the discovery and physiological function of mitochondrial-derived polypeptide MOTS-c, and the application of MOTS-c in the treatment of various diseases, such as aging, cardiovascular disease, insulin resistance, and inflammation. To provide additional ideas for future research and development, we tapped into the molecular mechanisms and therapeutic potentials of MOTS-c to improve diseases and combined the technology with synthetic biology in order to offer a new approach to its development and application.
Study Information
pubmed
2023
2023-01-25T00:00:00.000Z
10.3389/fendo.2023.1120533
22
50